In:
Transfusion Medicine and Hemotherapy, S. Karger AG, Vol. 21, No. 3 ( 1994), p. 143-149
Abstract:
〈 i 〉 Objective: 〈 /i 〉 To evaluate the anti-HCV (hepatitic C virus) reactivity for the development of an individual donor counseling strategy which would prevent unnecessary donor deferment without compromising the safety of blood products. 〈 i 〉 Design: 〈 /i 〉 All donors, who were repeatedly reactive in the Ortho HCV ELISA as well as the Abbott HCV EIA screening tests were selected for follow-up testing. At follow-up three screening tests (Ortho, Abbott, and UBI HCV EIA) and two confirmation tests (Riba 4 and PCR HCV RNA) were performed. During the counseling interview risk factors and medical history were recorded. 〈 i 〉 Setting: 〈 /i 〉 Blood bank Zuid-Limburg, Maastricht, the Netherlands; estimated donor population 17,500. 〈 i 〉 Participants: 〈 /i 〉 A total of 54 donors could be completely evaluated. 〈 i 〉 Results: 〈 /i 〉 The participants could be divided into five different categories, requiring specific donor information and different blood bank policies. The donors in categories 1 and 2 (n = 11) had false-positive reactions and were kept active. Category 3 and 4 donors (n = 28) showed indeterminate results and were permanently or temporarily excluded. Finally, in category 5 donors (n = 15) a HCV infection could be diagnosed on the basis of either Riba-positive or PCR-positive results. 〈 i 〉 Conclusions: 〈 /i 〉 An anti-HCV screening policy should include a careful evaluation and confirmation of antibody reactivity. A strategy is suggested which allows an individual donor counseling, prevents unnecessary donor deferment, and avoids unnecessary fear of seropositivity
Type of Medium:
Online Resource
ISSN:
1660-3796
,
1660-3818
Language:
English
Publisher:
S. Karger AG
Publication Date:
1994
detail.hit.zdb_id:
2100533-3
Bookmarklink